Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCrimson Tide Regulatory News (TIDE)

Share Price Information for Crimson Tide (TIDE)

Share Price is delayed by 15 minutes
Get Live Data
87.50    0.00 (0.00%)
Bid:
85.00
Ask:
90.00
Spread: 5.00 (5.882%)
Market Cap: £5.75m
TIDE Live PriceLast checked at - London Stock Exchange

Intraday Crimson Tide Share Chart

Contract Win

9 Apr 2010 07:00

RNS Number : 9258J
Crimson Tide PLC
09 April 2010
 



09 April 2010

Crimson Tide Plc

("Crimson Tide" or the "Company")

SMARTPHONE SYSTEM FROM CRIMSON TIDE EXTENDS BLOOD SAFETY SYSTEM TO PATIENTS' HOMES

Crimson Tide, the AIM quoted mobile data solutions provider, has signed a four year contract, worth up to €100,000 a year, for an advanced hand held system, mpro3hx, that enables Europe's first bar code safety system for blood disorder sufferers to be used at the patient's home. The contract, with Temperature Control Pharmaceuticals Limited (TCP) based in Dublin, is for up to 179 hand held units and is part of the National Haemophilia Project in Ireland.

The mobile software has been specifically designed by Crimson Tide and will run on a range of Windows Mobile™ smartphones supplied to the end user. Crimson Tide is a Microsoft Gold Certified Partner.

Says Crimson Tide's Executive Chairman Barrie Whipp: 'In terms of user numbers multiplied by length of contract this is our largest subscription deal to date. Our application is relevant to in-home patient drug administration worldwide , therefore we are anticipating extending our sales of this type of product in other marketplaces and for other patient uses.'

Derek McCormack, Managing Director of TCP said "TCP are delighted to work with Crimson Tide to roll out the Patient Handheld Devices for home treatment haemophiliapatients. They will help to further improve the quality service provided by TCP to home patients in Ireland."

The industry standard GS1 track-and-trace bar code system has been in use since 2005. It was devised as a result of a medical disaster in the 1980's in which contamination of blood products in Ireland led to 78 deaths when 200 haemophiliacs became infected with HIV and Hepatitis C.

With the new GS1 system, globally unique IDs assigned for each patient, product and location facilitate the automatic linking, capture and processing of data across the supply chain. Once a prescription is received for a patient or hospital delivery, all picking, packing and shipping is performed using barcode scanning, enabling each step in the cold chain delivery process to be validated.

Crimson Tide's innovation extends this traceability to the precise point of administration in the patient's home. Using the patient's mobile phone, the Company's system verifies the product ID (GTIN, batch/lot number, expiry date and serial number) before self-treatment is carried out. It can be used to alert patients of product recalls and, where there is more than one haemophilia patient in a household on different treatment, it ensures the right patient is treated with the right Coagulation Factor Concentrate (CFC) product.

In Ireland there are around 2,000 patients who suffer from some form of bleeding disorder, 200 of whom suffer from the severe type of haemophilia that requires intensive treatment, which means they self-medicate at home, work, school or on holiday. Crimson Tide's solution ensures that the right medication is administered at the right time, to the right patient in the right dose, by the right route.

Windows Mobile is a registered trademark of Microsoft Corporation in the United States and other countries.

- ends -

For further information, contact:

Crimson Tide plc

Barrie Whipp, Executive Chairman

 

01892 542 444

Threadneedle Communications

Graham Herring/Josh Royston

 

020 7653 9850

 

 

 

 

 

 

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
CNTUGURCCUPUGAR
Date   Source Headline
30th Apr 20079:15 amRNSAnnual Report and Accounts
19th Apr 20074:46 pmRNSDirector/PDMR Shareholding
29th Mar 20072:56 pmRNSFinal Results
22nd Mar 20072:42 pmRNSHolding(s) in Company
20th Mar 20079:31 amRNSNotice of Results
21st Dec 20062:26 pmRNSTotal Voting Rights
18th Dec 20062:52 pmRNSIssue of Equity
8th Dec 20067:01 amRNSIntelligent Data Acquisition
30th Nov 20066:16 pmRNSAcqu. and Trading Update
1st Nov 200610:36 amRNSBlocklisting Interim Review
12th Sep 20064:01 pmRNSDirector/PDMR Shareholding
22nd Aug 20067:00 amRNSFirst Day of Dealings
21st Aug 200611:42 amRNSEGM Statement
14th Aug 20065:50 pmRNSResult of AGM
14th Aug 20067:00 amRNSAGM Statement
4th Aug 20063:35 pmRNSSwansea Property
31st Jul 20061:35 pmRNSHolding(s) in Company
31st Jul 200611:39 amRNSHolding(s) in Company
27th Jul 20062:57 pmRNSSch 1 - Cohen(A.) & Co PLC
27th Jul 20067:01 amRNSAcquisition of Crimson Tide
30th Jun 20067:01 amRNSFinal Results
8th Mar 20062:39 pmRNSChange of registered address
2nd Mar 20067:00 amRNSChange of Adviser
8th Feb 20062:58 pmRNSDisposal
30th Sep 200511:41 amRNSInterim Results
30th Jun 20055:25 pmRNSFinal Results
21st Feb 200511:11 amRNSRule 8 - Cohen(A.) & Co PLC
21st Feb 200510:52 amRNSBoard Changes

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.